TY - JOUR AU - Yuan, Jun PY - 2018 DA - 2018/05/02 TI - Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials JO - BMC Pharmacology and Toxicology SP - 19 VL - 19 IS - 1 AB - Rivaroxaban, a direct factor Xa inhibitor, has seldom been used in patients with coronary artery disease. In this analysis, we aimed to systematically compare the efficacy and safety of rivaroxaban in addition to the anti-platelet regimen in patients with coronary artery disease. SN - 2050-6511 UR - https://doi.org/10.1186/s40360-018-0209-2 DO - 10.1186/s40360-018-0209-2 ID - Yuan2018 ER -